Full Text View
Tabular View
No Study Results Posted
Related Studies
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
This study has been completed.
Study NCT00002377   Information provided by Hoffmann-La Roche
First Received: November 2, 1999   Last Updated: July 1, 2005   History of Changes

November 2, 1999
July 1, 2005
 
 
 
 
Complete list of historical versions of study NCT00002377 on ClinicalTrials.gov Archive Site
 
 
 
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
 

To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.

 
Phase III
Interventional
Treatment, Parallel Assignment, Pharmacokinetics Study
  • Cytomegalovirus Retinitis
  • HIV Infections
  • Drug: Valganciclovir
  • Drug: Ganciclovir
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
 
 

Inclusion Criteria:

  • Documented AIDS diagnosis
  • Newly diagnosed peripheral CMV retinitis
  • More than 3 weeks of previous therapy for CMV retinitis
Both
14 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00002377
 
WV15376
Hoffmann-La Roche
 
 
Hoffmann-La Roche
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP